MetLife Investment Management LLC Increases Stock Holdings in Bioventus Inc. (NYSE:BVS)

MetLife Investment Management LLC increased its holdings in Bioventus Inc. (NYSE:BVS) by 129.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,981 shares of the company’s stock after acquiring an additional 12,949 shares during the quarter. MetLife Investment Management LLC’s holdings in Bioventus were worth $275,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BVS. SG Americas Securities LLC lifted its position in Bioventus by 100.4% during the second quarter. SG Americas Securities LLC now owns 25,315 shares of the company’s stock valued at $146,000 after buying an additional 12,684 shares during the period. Bank of New York Mellon Corp purchased a new position in Bioventus during the second quarter valued at $647,000. HB Wealth Management LLC purchased a new position in Bioventus during the second quarter valued at $60,000. Panagora Asset Management Inc. purchased a new position in Bioventus during the second quarter valued at $787,000. Finally, Rhumbline Advisers lifted its position in Bioventus by 5,367.9% during the second quarter. Rhumbline Advisers now owns 52,437 shares of the company’s stock valued at $302,000 after buying an additional 51,478 shares during the period. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on BVS shares. Canaccord Genuity Group raised their price objective on Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Craig Hallum lifted their price target on Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, September 27th.

Bioventus Price Performance

BVS opened at $11.68 on Monday. The stock has a 50-day moving average price of $12.14 and a 200-day moving average price of $9.37. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The firm has a market cap of $947.83 million, a PE ratio of -19.15 and a beta of 0.79. Bioventus Inc. has a 1 year low of $3.90 and a 1 year high of $14.38.

Bioventus (NYSE:BVS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.06. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. The firm had revenue of $138.96 million during the quarter, compared to analyst estimates of $132.57 million. During the same quarter in the previous year, the firm earned $0.05 EPS. Sell-side analysts predict that Bioventus Inc. will post 0.41 earnings per share for the current fiscal year.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.